Blog tagged as AI in Clinical Trials

At DPHARM 2025, Patrick McNamara, Chief Commercial Officer at Yunu, shared how Yunu is redefining imaging in clinical research by solving site-level challenges first.

At DPHARM, Paul McCracken, Founder and Principal of RadiaNova Consulting, sheds light on the hidden challenges of clinical trial imaging and how radiopharmaceutical studies are transforming its role.

Moe Alsumidaie interviewed Jeff Sorenson, CEO of Yunu, and Steve Tolle, Chief Product & Technology Officer at Ignitedata, on how the updated ICH E6(R3) guidance is transforming imaging in clinical trials.

Site-level imaging errors affect up to 50% of oncology trial reads, delaying trials and potentially censoring patients. When quality is enforced at the point of capture, error rates drop by more than 80%, saving millions of dollars and months in trial timelines.

Moe Alsumidaie’s latest article explores how the updated ICH E6(R3) guidance raises the bar for imaging in clinical trials. With imaging as the primary endpoint in most oncology studies, sites and sponsors must now meet the same Good Clinical Practice (GCP) standards as other critical data types.

Imaging is essential to trials but remains one of the most broken workflows. Yunu CEO Jeff Sorenson shares how real-time, connected platforms improve accuracy, speed, and patient outcomes by replacing outdated imaging processes.

With over two decades of experience in clinical research and business development, Patrick McNamara has played a pivotal role in Yunu’s rapid expansion across the pharmaceutical, biotech, and contract research organization (CRO) sectors.

This interview with Yunu CEO Jeffrey Sorenson explores how elevating imaging data in clinical trials can improve data integrity, trial efficiency, and patient outcomes, highlighting tech innovations and structural shifts needed for modern oncology research.

Emerging technologies are transforming pediatric oncology trials—boosting efficiency, protecting staff, and accelerating access to life-saving therapies through AI, real-world data, decentralized models, and digital tools.